{'fraction_non_alphanumeric': 0.024277456647398842, 'fraction_numerical': 0.011560693641618497, 'mean_word_length': 5.321167883211679, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Correlates of protection

Emerging Infections
Vaccines against Ebola virus (EBOV) are difficult to test in humans because of the sporadic nature of EBOV outbreaks. Therefore, understanding correlates of protection in preclinical models is necessary. Meyer et al. tested five candidate mucosal EBOV vaccines in cynomolgus macaques and showed that, despite sharing the same EBOV glycoprotein as an antigen, they varied in their ability to protect animals from EBOV challenge. The authors interrogated correlates of protection and found that functional qualities of the antibody response were associated with protection. By contrast, neutralizing antibody titers did not correlate with survival. Thus, looking beyond the presence of neutralizing antibodies may be necessary to understand the protective effect of EBOV vaccines.

Sci. Transl. Med. 13 , eabg6128 (2021).